AARD DEADLINE: Levi & Korsinsky Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline

Aardvark Therapeutics shares lost more than 70% of their IPO value following a Phase 3 safety pause and a subsequent FDA clinical hold on ARD-101. A securities class action alleges the company’s earlier claims that the drug was "99% gut-restricted" with minimal systemic exposure were materially misleading. The clinical hold substantially increases regulatory, litigation, and development-risk uncertainty for the company.

Analysis

The core investable issue is no longer a trial-timing delay but whether ARD-101's purported local pharmacology is credible enough to support any viable therapeutic window. A full hold forces a reset of probability of approval, duration, and required cash burn; for a single-asset or asset-concentrated biotech, that typically shifts valuation from NPV of a near-term launch to cash value less the cost of remediation. The litigation itself is secondary to the regulatory finding, but discovery could expose internal PK/safety data that impairs partnering leverage and management credibility.

Near term, the stock can remain technically vulnerable as IPO-era holders, healthcare specialists, and index/event-driven capital reassess ownership. The relevant 1-3 month catalyst is not a generic company update but the FDA's specific hold letter requirements: a limited monitoring/protocol amendment could preserve meaningful option value, while additional nonclinical toxicology, a dose-ranging redesign, or evidence of systemic exposure would likely extend the timeline by 12-24 months. Cash runway, quarterly operating burn, and any debt/covenant constraints determine whether a dilutive financing becomes the next catalyst.

Contrarian upside exists only if the issue is dose- or formulation-specific and the company can rapidly demonstrate exposure remains below a defined safety threshold. After a 70%+ decline, downside is not necessarily linear if enterprise value approaches net cash; however, absent verified cash-per-share and FDA remediation details, a directional short risks a sharp bear-market rally. Larger obesity/metabolic drug developers face little direct competitive benefit unless ARD-101 had a differentiated mechanism capable of taking clinically meaningful share.

Key Decisions for Investors

• Do not initiate a fresh AARD short solely on the headline. Set an alert for enterprise value falling below estimated net cash; at that point, cover/avoid shorts because residual pipeline and hold-resolution optionality can produce asymmetric upside.
• For a 1-3 month bearish expression, consider a small AARD put spread only after confirming option liquidity and borrow economics: buy 3-month ATM puts and sell puts 25-35% lower. The defined-risk structure targets further dilution/hold-duration repricing while limiting exposure to an FDA-resolution rally.
• Treat any long as a post-data event trade, not a dip-buy. Require disclosure of the FDA remediation plan, at least 12 months of runway after projected remediation costs, and evidence that systemic exposure is controllable before initiating; size as binary biotech risk.
• Monitor the next 10-Q for cash burn and legal-reserve language, plus any FDA correspondence describing required studies. A financing announcement before hold resolution or a requirement for new long-duration safety work falsifies a near-term recovery thesis.